Venture Advisors Iv Sbic, L... Net Worth

The estimated Net Worth of Venture Advisors Iv Sbic, L... is at least $2.74 Milion dollars as of 7 June 2016. Venture L owns over 414,286 units of Clearside Biomedical Inc stock worth over $2,738,123 and over the last 8 years Venture sold CLSD stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture L CLSD stock SEC Form 4 insiders trading

Venture has made over 2 trades of the Clearside Biomedical Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Venture bought 414,286 units of CLSD stock worth $2,900,002 on 7 June 2016.

The largest trade Venture's ever made was buying 414,286 units of Clearside Biomedical Inc stock on 7 June 2016 worth over $2,900,002. On average, Venture trades about 414,286 units every 0 days since 2016. As of 7 June 2016 Venture still owns at least 2,090,170 units of Clearside Biomedical Inc stock.

You can see the complete history of Venture L stock trades at the bottom of the page.

Insiders trading at Clearside Biomedical Inc

Over the last 8 years, insiders at Clearside Biomedical Inc have traded over $11,999,807 worth of Clearside Biomedical Inc stock and bought 4,477,928 units worth $22,264,136 . The most active insiders traders include Bradford T Whitmore, Clay Thorp oraz Venture Advisors Iv Sbic, L.... On average, Clearside Biomedical Inc executives and independent directors trade stock every 30 days with the average trade being worth of $82,593. The most recent stock trade was executed by Ngai Hang Victor Chong on 24 June 2024, trading 23,500 units of CLSD stock currently worth $24,910.

What does Clearside Biomedical Inc do?

clearside biomedical, inc. is a pharmaceuticals company located in 1220 old alpharetta rd., suite 300, alpharetta, ga, united states.

Complete history of Venture L stock trades at Clearside Biomedical Inc

Clearside Biomedical Inc executives and stock owners

Clearside Biomedical Inc executives and other stock owners filed with the SEC include:

• George Lasezkay,
  President, Chief Executive Officer, Director
• Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.,
  Pres, CEO & Director
• Dr. George M. Lasezkay Pharm.D., Pharma.D., J.D.,
  Pres, CEO & Director
• Charles Deignan,
  Chief Financial Officer
• Dr. Thomas A. Ciulla M.B.A., M.D.,
  Chief Medical Officer & Chief Devel. Officer
• Charles A. Deignan,
  Chief Financial Officer
• Jenny Kobin,
  IR Contact Officer
• Clay Thorp,
  Independent Director
• Nancy Hutson,
  Independent Director
• William Humphries,
  Independent Director
• Jeffrey Edwards,
  Independent Director
• Richard Croarkin,
  Independent Director
• Christy Shaffer,
  Independent Chairman of the Board
• Susan L. Coultas Ph.D.,
  Chief Clinical Officer
• Rick McElheny,
  VP of Corp. Devel.
• Leslie B. Zacks,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Jenny R. Kobin,
  Head of Investor Relations
• Venture Advisors Iii, Llc H...,
  
• Venture Advisors Iv Sbic, L...,
  
• Venture Advisors Iii, Llc H...,
  
• Evgeny Zaytsev,
  Director
• Daniel H. White,
  President and CEO
• Investments S.A.R.L.Rusnano...,
  
• Derek Yoon,
  Director
• Gerald D. Cagle,
  Director
• Venture Advisors Iv Sbic, L...,
  
• Glenn Noronha,
  Executive Vice President, R&D
• Thomas Ciulla,
  Chief Medical Officer
• Brion S. Raymond,
  Chief Commercial Officer
• Anthony S Gibney,
  
• Bradford T Whitmore,
  10% owner
• Ngai Hang Victor Chong,
  Chief Medical Officer
• Benjamin R Yerxa,